CD4 and neoplasm: Wang et al. constructed a prognostic model based on the expressional signature of 12 snoRNAs whose risk score was positively correlated with the presence of naive B-cells and CD4+ T-cells in the tumor microenvironment and had potential for predicting patient sensitivity to immune checkpoint inhibition therapies (Table 1) [128].